Hela Cell Or Derivative Patents (Class 435/367)
  • Patent number: 11278633
    Abstract: The invention, in some aspects, relates to dummy-fluorescent (DF) polypeptide molecules and their encoding nucleic acid molecules and use of such molecules in fusion proteins and their encoding nucleic acid molecules. Compositions of the invention may be delivered to cells and subjects and used in methods to modulate electrical activity of cells in which they are expressed, and for treatment of diseases and conditions in subjects.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: March 22, 2022
    Assignee: Massachusetts Institute of Technology
    Inventors: Aimei Yang, Demian Park, Kiryl Piatkevich, Edward Boyden
  • Patent number: 9267099
    Abstract: Disclosed herein are capillary fabrication devices comprising living cells within a support medium. Culture of the cells produces viable lumenized capillary networks with natural or pre-determined geometries and ECM and basement membrane associated with the capillary networks. The capillary networks and the ECM and basement membrane detachable from the capillary networks are useful for tissue engineering applications.
    Type: Grant
    Filed: March 15, 2011
    Date of Patent: February 23, 2016
    Assignee: Indiana University Research and Technology Corporation
    Inventors: James A. Glazier, Abdelkrim Alileche, Abbas Shrinifard, Dragos Amarie
  • Publication number: 20150139953
    Abstract: Sequences of a serotype 8 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles.
    Type: Application
    Filed: January 16, 2015
    Publication date: May 21, 2015
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Publication number: 20150132330
    Abstract: Provided herein are flu hemagglutinin polypeptides, including chimeric influenza virus hemagglutinin polypeptides, and flu hemagglutinin polypeptides comprising modified glycosylation sites and non-naturally glycosylation sites, compositions comprising the same, vaccines comprising the same and methods of their use.
    Type: Application
    Filed: September 19, 2012
    Publication date: May 14, 2015
    Inventors: Adolfo Garcia-Sastre, Peter Palese, Florian Krammer, Natalie Pica, Dirk Eggink, Rafael A. Medina-Silva, Rong Hai
  • Publication number: 20150132277
    Abstract: Isolated monomeric aminoacyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
    Type: Application
    Filed: October 9, 2014
    Publication date: May 14, 2015
    Inventors: Paul Schimmel, Xiang-Lei Yang, Bonnie Slike
  • Publication number: 20150126410
    Abstract: The invention relates in a first embodiment to a method for increasing the yield of replication-incompetent adenoviruses having at least a partial deletion in the E1-region, wherein said adenoviruses are generated in a production cell, the method comprising the steps of: (a) expressing in said production cell an adenoviral pIX polypeptide from a nucleic acid sequence encoding said adenoviral pIX polypeptide under the control of (i) at least a minimal endogenous pIX promoter and a heterologous promoter; or (ii) a heterologous promoter; and (b) expressing in said production cell the elements necessary for the production and assembly of said adenoviruses from corresponding coding sequences, thereby increasing the yield of said adenoviruses generated in said production cell in comparison to the yield of replication-incompetent adenoviruses having at least a partial deletion in the E1-region generated in said production cell in the absence of said nucleic acid sequence encoding said adenoviral pIX polypeptide.
    Type: Application
    Filed: July 4, 2013
    Publication date: May 7, 2015
    Inventors: Christian Thirion, Zsolt Ruzsics
  • Publication number: 20150125893
    Abstract: The invention provides fusion proteins comprising at least one fluorescent protein that is linked to at least one transporter protein that changes three-dimensional conformation upon specifically transporting its substrate. The transporter protein may be a nitrate transporter, a peptide transporter, or a hormone transporter. The invention provides fusion proteins comprising at least one fluorescent protein that is linked to at least one mechanosensitive ion channel protein. The invention also provides for methods of using the fusion proteins of the present invention and nucleic acids encoding the fusion proteins.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 7, 2015
    Inventors: Wolf B. Frommer, Cheng-Hsun Ho
  • Publication number: 20150110825
    Abstract: The present invention provides nanoparticles and compositions of various constructs that combine meta-stable viral proteins (e.g., RSV F protein) and self-assembling molecules (e.g., ferritin, HSPs) such that the pre-fusion conformational state of these key viral proteins is preserved (and locked) along with the protein self-assembling into a polyhedral shape, thereby creating nanoparticles that are effective vaccine agents. The invention also provides nanoparticles comprising a viral fusion protein, or fragment or variant thereof, and a self-assembling molecule, and immunogenic and vaccine compositions including the same.
    Type: Application
    Filed: September 24, 2014
    Publication date: April 23, 2015
    Inventors: Ram SASISEKHARAN, Aditya RAGURAM, Vidya SUBRAMANIAN
  • Publication number: 20150111222
    Abstract: The present disclosure provides, inter alia, genetically encoded recombinant peptide biosensors comprising analyte-binding framework portions and signaling portions, wherein the signaling portions are present within the framework portions at sites or amino acid positions that undergo a conformational change upon interaction of the framework portion with an analyte.
    Type: Application
    Filed: August 8, 2012
    Publication date: April 23, 2015
    Applicant: HOWARD hUGHES MEDICAL INSTITUTE
    Inventors: Jonathan Marvin, Loren Looger, Richard T. Lee, Eric Schreiter
  • Publication number: 20150111233
    Abstract: Luciferases which are different from those known heretofore have been desired. A luciferase mutant comprising an amino acid sequence in which at least one amino acid selected from the group consisting of valine at the position of 44, alanine at the position of 54 and tyrosine at the position of 138 is substituted with other amino acid(s) in the amino acid sequence of SEQ ID NO: 2.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 23, 2015
    Inventors: Satoshi INOUYE, Junichi SATO
  • Publication number: 20150110836
    Abstract: The present disclosure provides compositions and methods for the generation of an antibody or immunogenic composition, such as a vaccine, through epitope focusing by variable effective antigen surface concentration. Generally, the composition and methods of the disclosure comprise three steps: a “design process” comprising one or more in silico bioinformatics steps to select and generate a library of potential antigens for use in the immunogenic composition; a “formulation process”, comprising in vitro testing of potential antigens, using various biochemical assays, and further combining two or more antigens to generate one or more immunogenic compositions; and an “administering” step, whereby the immunogenic composition is administered to a host animal, immune cell, subject or patient. Further steps may also be included, such as the isolation and production of antibodies raised by host immune response to the immunogenic composition.
    Type: Application
    Filed: May 21, 2013
    Publication date: April 23, 2015
    Inventor: Jacob E. Glanville
  • Publication number: 20150105315
    Abstract: The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase or variants thereof possessing endonuclease activity, wherein said PA subunit is from a virus belonging to the Orthomyxoviridae family. This invention also relates to (i) crystals of the polypeptide fragments which are suitable for structure determination of said polypeptide fragments using X-ray crystallography and (ii) computational methods using the structural coordinates of said polypeptide to screen for and design compounds that modulate, preferably inhibit the endonucleolytically active site within the polypeptide fragment. In addition, this invention relates to methods identifying compounds that bind to the PA polypeptide fragments possessing endonuclease activity and preferably inhibit said endonucleolytic activity, preferably in a high throughput setting.
    Type: Application
    Filed: October 21, 2014
    Publication date: April 16, 2015
    Applicants: EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL), UNIVERSITY JOSEPH FOURIER FILIALE, Centre National de la Recherche Scientifique - Direction de la Politique Industrielle
    Inventors: Denis Bouvier, Thibaut Crepin, Rob Ruigrok, Alexander Dias, Stephen Cusack
  • Publication number: 20150104450
    Abstract: Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.
    Type: Application
    Filed: March 11, 2013
    Publication date: April 16, 2015
    Inventors: Ralph Minter, Julie Douthwaite, Jacques Moisan, Michael Bowen, Steven Rust, Cyril Privezentzev
  • Publication number: 20150098956
    Abstract: Recombinant polypeptides comprising a DR?1 domain, an antigenic peptide, and a linker sequence are disclosed. The linker sequence comprises a first glycine-serine spacer, a thrombin cleavage site and a second glycine-serine spacer. Further disclosed are pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said pharmaceutical compositions, and expression constructs comprising nucleic acids that encode the recombinant polypeptides.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventors: Arthur A. Vandenbark, Roberto Meza-Romero, Gil Benedek, Gregory G. Burrows
  • Publication number: 20150087596
    Abstract: The present invention relates to Huwentoxin-IV variants, polynucleotides encoding them, methods of making and using the foregoing, and methods of alleviating pain with peptide inhibitors of Nav1.7.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 26, 2015
    Inventors: William Eckert, Mack Flinspach, Michael Hunter, Yi Liu, Robert Neff, Alan Wickenden, Alan Gibbs
  • Publication number: 20150079127
    Abstract: The present invention relates to the field of veterinary parasitology, especially of canine Babesiosis. In particular the invention relates to a polypeptide being a novel canine Babesia antigen (CBA), or fragments thereof, and to compositions comprising this antigen, to nucleic acids encoding the antigen, antibodies against the antigen, and medical uses of this antigen, fragments, antibodies, or encoding nucleic acids. In particular the invention relates to the use of such components in vaccines against canine Babesiosis.
    Type: Application
    Filed: December 2, 2014
    Publication date: March 19, 2015
    Inventors: Theodorus Petrus Maria Schetters, Karina Moubri-Menage, Jos Kleuskens, Andreas Walter Claudius Rohwer
  • Publication number: 20150071858
    Abstract: The present invention relates to the use of p11 as a drug target as well as a tool for the diagnosis, treatment and development of p11/5-HT receptor related disorders. The invention further relates to p11 knock-out animals as well as p11 transgenic animals and their use as models for the development of novel psychotherapeutic agents, and to methods of diagnosis, prophylaxis and treatment of p11/5-HT receptor related disorders.
    Type: Application
    Filed: August 5, 2014
    Publication date: March 12, 2015
    Inventors: Per SVENNINGSSON, Paul GREENGARD
  • Publication number: 20150072353
    Abstract: Analyte sensors, methods for producing and using analyte sensors, methods of detecting and/or measuring analyte activity, detecting pH change, and/or, controlling the concentration of an analyte in a system, are disclosed. Embodiments of the analyte sensors according to the disclosure can provide an accurate and convenient method for characterizing analyte activity, detecting pH change, controlling the concentration of an analyte in a system, and the like, in both in vivo and in vitro environments, in particular in living cell imaging.
    Type: Application
    Filed: August 21, 2014
    Publication date: March 12, 2015
    Inventors: Jenny Jie Yang, Shen Tang
  • Publication number: 20150071883
    Abstract: The invention provides improved adeno-associated virus (AAV) Factor VIII (FVIII) vectors, including AAV FVIII vectors that produce a functional Factor VIII polypeptide and AAV FVIII vectors with high expression activity.
    Type: Application
    Filed: September 10, 2014
    Publication date: March 12, 2015
    Inventor: Peter Cameron Colosi
  • Publication number: 20150065560
    Abstract: The present invention relates to a one-vector expression system comprising a sequence encoding two polypeptides, such as tyrosine hydroxylase (TH) and GTP-cyclohydrolase 1 (GCH1). The two polypeptides can be should preferentially be expressed at a ratio between 3:1 and 15:1, such as between 3:1 and 7:1. The invention is useful in the treatment of catecholamine deficient disorders, such as dopamine deficient disorders including but not limited to Parkinson's Disease. Moreover, the present invention provides a method to deliver the vector construct in order to limit the increased production of the catecholamine to the cells in need thereof.
    Type: Application
    Filed: April 1, 2014
    Publication date: March 5, 2015
    Inventors: Tomas Björklund, Anders Björklund, Deniz Kirik
  • Publication number: 20150064157
    Abstract: The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor.
    Type: Application
    Filed: November 7, 2014
    Publication date: March 5, 2015
    Inventors: Jonathan H. LeBowitz, John Maga
  • Publication number: 20150064716
    Abstract: The present invention provides native Goodpasture antigen binding protein isoforms, monoclonal antibodies directed against such proteins, and methods for their use.
    Type: Application
    Filed: November 17, 2014
    Publication date: March 5, 2015
    Inventors: Juan Saus, Fernando Revert
  • Publication number: 20150065436
    Abstract: The present invention relates to peptidomimetics that mimic helix ?B of the C-terminal transactivation domain of HIF-1?. Methods of using the peptidomimetics to, e.g., inhibit the HIF-1?-p300/CBP interaction, are also disclosed.
    Type: Application
    Filed: September 3, 2014
    Publication date: March 5, 2015
    Applicants: UNIVERSITY OF SOUTHERN CALIFORNIA, NEW YORK UNIVERSITY
    Inventors: Paramjit S. ARORA, Brooke Bullock LAO, Laura K. HENCHEY, Nathaniel J. TRAASETH, Paul THOMSON, Swati KUSHAL, Bogdan Z. OLENYUK
  • Publication number: 20150057191
    Abstract: Compositions are provided, which can be used as frameworks for the creation of very stable and soluble single-chain Fv antibody fragments. These frameworks have been selected for intracellular performance and are thus ideally suited for the creation of scFv antibody fragments or scFv antibody libraries for applications where stability and solubility are limiting factors for the performance of antibody fragments, such as in the reducing environment of a cell. Such frameworks can also be used to identify highly conserved residues and consensus sequences which demonstrate enhanced solubility and stability.
    Type: Application
    Filed: August 26, 2014
    Publication date: February 26, 2015
    Inventors: Kathrin Tissot, Stefan Ewert, Adrian Auf Der Maur, Alcide Barberis, Dominik Escher
  • Publication number: 20150056271
    Abstract: Factor VIII variants and methods of use thereof are disclosed.
    Type: Application
    Filed: August 25, 2014
    Publication date: February 26, 2015
    Inventors: Valder Arruda, Rodney Camire, Nicholas Iacobelli
  • Patent number: 8961977
    Abstract: The present invention relates to an anti-idiotypic polypeptide scaffold that includes two or more peptide sequences that mimic a discontinuous epitope of a pathogen that is recognized by or induces formation of a broadly neutralizing antibody. Using a fibronectin FNfn10 scaffold bearing two or more modified discontinuous loops, scaffolds that recognize broadly neutralizing antibodies in vitro and from patient serum have been identified. These scaffolds should induce an immune response or mobilize germline specificities to initiate their affinity maturation.
    Type: Grant
    Filed: February 14, 2011
    Date of Patent: February 24, 2015
    Assignee: University of Rochester
    Inventors: Stephen Dewhurst, Mark A. Sullivan
  • Publication number: 20150050264
    Abstract: The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases.
    Type: Application
    Filed: September 7, 2012
    Publication date: February 19, 2015
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Denis VIVIEN, Jerome PARCQ, Denis VIVIEN, Jerome PARCQ
  • Publication number: 20150044170
    Abstract: The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver genes encoding human immunodeficiency virus entry inhibitors to target cells in mammals.
    Type: Application
    Filed: April 9, 2014
    Publication date: February 12, 2015
    Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.
    Inventors: Philip R. Johnson, JR., Kelly Reed Clark
  • Publication number: 20150038675
    Abstract: The purpose of the present invention is to provide: a peptide having an affinity for silicon nitride; a polynucleotide encoding the peptide; an expression vector for expressing the peptide having an affinity for silicon nitride; an expression vector for expressing a peptide fusion protein that comprises the peptide having an affinity for silicon nitride and a target protein; a transformant obtained by introducing the expression vector into a host cell; a peptide fusion protein obtained from the transformant; a silicon nitride substrate to which a peptide having an affinity for silicon nitride has been bonded; a method for immobilizing a target protein to a silicon nitride substrate; a composition for immobilizing a target protein to a silicon nitride substrate, the composition comprising a peptide having an affinity for silicon nitride; and a linker for immobilizing a target protein to a silicon nitride substrate, the linker comprising a peptide having an affinity for silicon nitride.
    Type: Application
    Filed: February 12, 2013
    Publication date: February 5, 2015
    Inventors: Yoichi Kumada, Michimasa Kishimoto, Takeru Otsuka
  • Publication number: 20150037872
    Abstract: The present invention relates to a method of selecting a protein variant having modified immunogenicity as compared to the parent protein comprising the steps obtaining antibody binding peptide sequences, using the sequences to localise epitope sequences on the 3-dimensional structure of parent protein, defining an epitope area including amino acids situated within 5 ? from the epitope amino acids constituting the epitope sequence, changing one or more of the amino acids defining the epitope area of the parent protein by genetical engineering mutations of a DNA sequence encoding the parent protein, introducing the mutated DNA sequence into a suitable host, culturing said host and expressing the protein variant, and evaluating the immunogenicity of the protein variant using the parent protein as reference. The invention further relates to the protein variant and use thereof, as well as to a method for producing said protein variant.
    Type: Application
    Filed: October 15, 2014
    Publication date: February 5, 2015
    Inventors: Erwin Ludo Roggen, Steffen Ernst, Allan Svendsen, Esben Peter Friis, Claus Von Der Osten
  • Publication number: 20150031618
    Abstract: The present disclosure relates to a collection of novel muteins derived from human ?1m (or a1m) polypeptide or a functional homologue thereof. The disclosure further refers to a ?1m mutein capable of specifically binding to one or more targets other than a target to which wild-type ?1m binds. The disclosure also relates to a method for producing such collection of muteins and a method for isolating a mutein capable of binding one or more such non-natural targets of wild-type ?1m polypeptide. These aspects are made possible due to, e.g, the structural elucidation of ?1m disclosed herein by the present inventors, an appreciation of ligand-binding sights thereof and, hence, an understanding of which amino acid positions are most suitable for mutagenesis for re-engineering specificity and affinity for any given target while maintaining the secondary and/or tertiary structure of ?1m.
    Type: Application
    Filed: January 31, 2013
    Publication date: January 29, 2015
    Inventors: Arne Skerra, Winfried Meining, Evelyn Eggenstein
  • Publication number: 20150023960
    Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
    Type: Application
    Filed: March 8, 2013
    Publication date: January 22, 2015
    Inventors: Darrin Anthony Lindhout, Peng Zhang, Thomas Frederick Parsons
  • Publication number: 20150023995
    Abstract: The present invention provides polypeptides having a composite amino acid sequence derived from a consensus sequence representing the capsid proteins of two or more circulating strains of a non-enveloped virus. In particular, the invention provides virus-like particles comprising at least one composite polypeptide. Such virus-like particles have antigenic epitopes of two or more circulating strains of a non-enveloped virus and produce an increase in antisera cross-reactivity to one or more circulating strains of the non-enveloped virus. Methods of making composite virus-like particles and vaccine formulations comprising composite virus-like particles are also disclosed.
    Type: Application
    Filed: July 25, 2014
    Publication date: January 22, 2015
    Applicant: TAKEDA VACCINES, INC.
    Inventors: Charles RICHARDSON, Robert F. BARGATZE, Joel HAYNES, Bryan STEADMAN
  • Publication number: 20150004690
    Abstract: The invention describes novel virus-like particles for use as vaccines, diagnostic tools and R&D tools based on recombinant DNA and cell cultivation techniques for production. The recombinant virus-like particles of the invention are assembled by polypeptide chains that incorporate several, in particular two or more, different epitopes which are selected either (a) from different viral strains of the same virus and/or (b) from different serotypes of the same virus and/or (c) from different viral strains specific for different hosts. These epitopes are then displayed on the particle surface.
    Type: Application
    Filed: August 29, 2014
    Publication date: January 1, 2015
    Inventors: Corinne JOHN, Christian SCHAUB, Sabine WELLNITZ
  • Patent number: 8911776
    Abstract: The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: December 16, 2014
    Inventor: Claresa Levetan
  • Publication number: 20140356960
    Abstract: The present invention relates to a nucleic acid containing at least one homing endonuclease site (HE) and at least one restriction enzyme site (X) wherein the HE and X sites are selected such that HE and X result in compatible cohesive ends when cut by the homing endonuclease and restriction enzyme, respectively, and the ligation product of HE and X cohesive ends can neither be cleaved by the homing endonuclease nor by the restriction enzyme. Further subject-matter of the present invention relates to a vector comprising the nucleic acid of the present invention, host cells containing the nucleic acid and/or the vector; a kit for cloning and/or expression of multiprotein complexes making use of the vector and the host cells, a method for producing a vector containing multiple expression cassettes, and a method for producing multiprotein complexes.
    Type: Application
    Filed: April 25, 2014
    Publication date: December 4, 2014
    Inventor: Imre Berger
  • Publication number: 20140356871
    Abstract: The disclosure relates to the field of human genetics, particularly the field of peripheral neuropathy, particularly inherited peripheral neuropathy. Specifically, the disclosure relates to methods and materials to detect hereditary peripheral neuropathy, more particularly autosomal recessive Charcot-Marie-Tooth disease.
    Type: Application
    Filed: January 10, 2013
    Publication date: December 4, 2014
    Applicant: VIB VZW
    Inventors: Albena Jordanova, Magdalena Zimon, Jonathan Baets, Peter De Jonghe
  • Publication number: 20140356905
    Abstract: Compositions and methods for large-scale recombinant protein expression are disclosed.
    Type: Application
    Filed: June 3, 2014
    Publication date: December 4, 2014
    Applicant: Rutgers, The State University of New Jersey
    Inventors: John D. Altman, John C. Shires, Ankita Basant, Jillian Whidby, Joseph Marcotrigiano, Abdul G. Khan
  • Publication number: 20140348817
    Abstract: Methods and diagnostic agents for identification of subjects for cancer treatment with an anti-hyaluronan agent, such as a hyaluronan-degrading enzyme, are provided. Diagnostic agents for the detection and quantification of hyaluronan in a biological sample and monitoring cancer treatment with an anti-hyaluronan agent, for example a hyaluronan-degrading enzyme, are provided. Combinations and kits for use in practicing the methods also are provided.
    Type: Application
    Filed: August 14, 2014
    Publication date: November 27, 2014
    Inventors: Ping Jiang, H. Michael Shepard, Lei Huang
  • Publication number: 20140343130
    Abstract: The present disclosure provides non-naturally occurring miR-196a-2 miRNAs and non-naturally occurring miR-204 miRNAs. The non-naturally occurring miRNAs of the disclosure have mature strand sequences distinct from their endogenous counterparts. The disclosure also provides methods of selecting mature strand sequences that function optimally in non-naturally occurring miR-196a-2 miRNAs. The methods and compositions of the disclosure may be used to mediate gene silencing via the RNAi pathway.
    Type: Application
    Filed: August 7, 2014
    Publication date: November 20, 2014
    Inventors: Melissa Kelley, Amanda Birmingham, Jon Karpilow, Anastasia Khvorova, Kevin Sullivan
  • Publication number: 20140335053
    Abstract: The present invention discloses the identification and isolation of novel MHC class II epitopes derived from the cancer antigen, NY ESO-1. The novel MHC class II epitopes from NY-EsO-1 are recognized by CD4+ T lymphocytes in an HLA class II restricted manner, in particular HLA-DR or HLA-DP restricted. The products of the gene are promising candidates for immunotherapeutic strategies for the prevention, treatment and diagnosis of patients with cancer.
    Type: Application
    Filed: May 22, 2014
    Publication date: November 13, 2014
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Rong-Fu Wang, Steven A. Rosenberg, Gang Zeng
  • Publication number: 20140335539
    Abstract: A method for detecting an interaction between a first protein and a second protein comprises the steps of: expressing in a cell a first fusion protein comprising the first protein and an association-inducing protein, and a second fusion protein comprising the second protein and a fluorescent protein having a multimerization ability; detecting a fluorescent focus formed by an association between the first fusion protein and the second fusion protein in the cell; and determining an interaction between the first protein and the second protein according to the detection of the fluorescent focus.
    Type: Application
    Filed: December 5, 2012
    Publication date: November 13, 2014
    Applicant: MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.
    Inventors: Taku Watanabe, Tatsuya Seki, Aki Fujioka
  • Publication number: 20140335568
    Abstract: The present disclosure relates to a nucleic acid assembly (NAA), comprising sensor domain and handle domain; an assembly interfaceable motif (AIM) sequence optionally along with intracellular targeting motif (ITM) sequence; and an AIM-NAA complex. It also relates to a vector comprising assembly interfaceable motif sequence optionally along with intracellular targeting motif sequence and a cell comprising the vector. Further, the instant disclosure also provides a method to obtain the nucleic acid assembly, method of intracellular targeting and kit thereof.
    Type: Application
    Filed: October 11, 2012
    Publication date: November 13, 2014
    Applicant: NATIONAL CENTRE FOR BIOLOGICAL SCIENCES
    Inventors: Yamuna Krishnan, Souvik Modi
  • Publication number: 20140328875
    Abstract: Provided herein are chimeric influenza hemagglutinin (HA) polypeptides, compositions comprising the same, vaccines comprising the same, and methods of their use.
    Type: Application
    Filed: December 17, 2013
    Publication date: November 6, 2014
    Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Adolfo Garcia-Sastre, Peter Palese, Florian Krammer
  • Publication number: 20140323348
    Abstract: Disclosed are methods of promoting and/or enhancing G-Protein Coupled Receptor (GPCR) localization to the cell membrane and/or cell surface; methods of promoting and/or enhancing GPCR functional expression; and methods and assays for screening or identifying ligands (e.g., agonists or antagonists) that bind GPCRs. Also provided are vectors, recombinant cells, and stable cell lines for use in the methods and assays.
    Type: Application
    Filed: November 30, 2012
    Publication date: October 30, 2014
    Inventors: Hiroaki Matsunami, Yue Jiang, Ming-Shan Chien
  • Publication number: 20140323401
    Abstract: The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex. In particular, the present invention is drawn to tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are not involved in the binding of the ligand to the receptor complex, e.g., to the EPO receptor homodimer. Accordingly, the tissue protective peptides of the invention are derived from the amino acid sequences of regions of cytokine receptor ligands that are generally located on or within the region of the ligand protein that is opposite of the receptor complex, i.e., are generally derived from amino acid sequences of regions of the ligand protein that face away from the receptor complex while the ligand is bound to the receptor.
    Type: Application
    Filed: April 8, 2014
    Publication date: October 30, 2014
    Applicant: Araim Pharmaceuticals, Inc.
    Inventors: Anthony CERAMI, Michael BRINES, Thomas COLEMAN
  • Publication number: 20140315804
    Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.
    Type: Application
    Filed: March 13, 2014
    Publication date: October 23, 2014
    Applicant: GENZYME CORPORATION
    Inventors: Peter PECHAN, Jeffery ARDINGER, Hillard RUBIN, Samuel WADSWORTH, Abraham SCARIA
  • Publication number: 20140314758
    Abstract: Immunogenic peptides from tumor associated stromal cell antigens, including combinations of such peptides, are disclosed herein. In some examples the peptides are useful for methods of eliciting an immune response. In additional examples the peptides are useful for methods of treating cancer. Methods for decreasing vascularization of a tumor using a Protein Delta Homolog 1 (DLK1) protein or a nucleic acid encoding the protein are also disclosed.
    Type: Application
    Filed: November 15, 2012
    Publication date: October 23, 2014
    Applicant: University of Pittsburgh- Of the Commonwealth System of Higher Education
    Inventors: Walter J. Storkus, Anamika Bose, Jennifer Lynn Taylor, Xi Zhao, Devin B. Lowe
  • Publication number: 20140308704
    Abstract: The present invention relates to a cell line in which an expression construct is introduced into a genomic DNA, the expression construct including: (a) a promoter operable in animal cells and heterologous to adenoviruses; and (b) a modified adenovirus E1 coding gene sequence of SEQ ID NO:1 operatively linked to the promoter. According to the present invention, the cell line of the present invention is a novel cell line which is less likely to produce a replication competent adenovirus (RCA). The adenovirus producing cell line of the present invention has a low possibility of producing RCA due to homologous recombination, when compared with conventional cell lines. Therefore, this makes it possible to regulate the required amount of virus during gene therapy using the adenovirus and prevent tissue damage and toxic effects caused by overproduction of the adenovirus.
    Type: Application
    Filed: November 22, 2012
    Publication date: October 16, 2014
    Inventors: Seung Shin Yu, Chang-Wan Joo, Jin-A Chae, Yeon Suk Cha
  • Publication number: 20140310830
    Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.
    Type: Application
    Filed: December 12, 2013
    Publication date: October 16, 2014
    Inventors: Feng ZHANG, Le CONG, Fei RAN